Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed? - sprookjes - yvandenbroek - TriplyDB

Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?

Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?

http://www.wikidata.org/entity/Q35076287

about

Vaccines targeting the neovasculature of tumors A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.

P2860

Q34704905-9342D3FE-36EA-435F-9879-537D01B4E674 Q51319007-FECA50CD-DAD2-4745-BD92-B8E1F9D5D127

P2860

Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?

http://www.wikidata.org/entity/Q35076287

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Bevacizumab in the treatment o ...... cancer: where have we landed?

@ast

Bevacizumab in the treatment o ...... cancer: where have we landed?

@en

type

label

Bevacizumab in the treatment o ...... cancer: where have we landed?

@ast

Bevacizumab in the treatment o ...... cancer: where have we landed?

@en

prefLabel

Bevacizumab in the treatment o ...... cancer: where have we landed?

@ast

Bevacizumab in the treatment o ...... cancer: where have we landed?

@en

P1433

Q35076287-C3D6BD0F-C071-48BE-99A0-6E3A2AB11632

P1476

Q35076287-4EA9C008-4EB2-4B98-BF43-EF56B092496E

P2093

Q35076287-10C58988-E4E0-48C5-9F83-C1792D8A5FEA

Q35076287-4C157F5E-51F3-42FA-B4D3-B7EF87F99D80

Q35076287-E1314B3F-3B2D-4589-BE49-5C448AC34878

Q35076287-F397C435-C0D4-400E-AAAB-3936E92ABD4C

P2860

Q35076287-009C5C05-8969-443A-AF52-6436C40604BF

Q35076287-14BDD6BB-691F-443E-8E61-6CD197EF269F

Q35076287-1AD7164D-AF74-4613-AB11-D3A70FEC7862

Q35076287-1AF05B9D-3188-48D3-AE1C-85630C0015EC

Q35076287-1B69870A-4FD4-459B-8094-A06329F59B5E

Q35076287-1E9CA219-A4B8-45A5-997D-FABCAAF9C9CB

Q35076287-23DEDFDC-830C-4CC1-9A6E-58DDEA7D31DF

Q35076287-2410D11D-B8AC-4302-8641-010031B33E51

Q35076287-24C8CAB4-EF98-4A23-A180-77D74966AE54

Q35076287-3D2FEF91-D2FC-42A2-84E2-A7A9009171A1

P304

Q35076287-13D1D96E-73A3-467C-9870-08914DE843E0

P31

Q35076287-2B940659-C3E1-47DA-9A12-45D00F02A067

P356

Q35076287-0A161E84-A98C-41E1-B8B3-FA86B6AF4160

P433

Q35076287-C2FCAAC8-579D-413C-BDFA-F8261E3C113B

P478

Q35076287-9553F0C0-747D-4E3B-8E90-7217F670C2F0

P577

Q35076287-B14EBBC4-D17F-477A-97C6-09BCD49E94D7

P5875

Q35076287-5C56B228-5240-4B6D-A6E9-F6084835B5F1

P698

Q35076287-533A7EEC-D086-4224-8BE6-0D8CB5803C2D

P921

Q35076287-2C2DC230-68DA-474A-9A25-64615705B144

P932

Q35076287-1C7604E0-F316-4994-95B4-21A85D7FC4BA

P356

1758834010376301

P1433

Therapeutic advances in medical oncology

P1476

Bevacizumab in the treatment o ...... cancer: where have we landed?

@en

P2093

A M Prove

http://www.w3.org/2001/XMLSchema#string

L Y Dirix

http://www.w3.org/2001/XMLSchema#string

P A Van Dam

http://www.w3.org/2001/XMLSchema#string

P B Vermeulen

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF inhibition and renal thrombotic microangiopathy

Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer.

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

The biology of vascular endothelial growth factor

Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.

High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.

P304

331-342

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758834010376301

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51521185

http://www.w3.org/2001/XMLSchema#string

P698

21789145

http://www.w3.org/2001/XMLSchema#string

P921

P932

3126024

http://www.w3.org/2001/XMLSchema#string